Kolexia
Girard Nicolas Pneumologie
Girard Nicolas
Pneumologie
Clcc Institut Curie
Paris, France
904 Activités
2.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Tumeurs du thymus Thymome Métastase tumorale Adénocarcinome Tumeurs épithéliales épidermoïdes et glandulaires

Collaborateurs

Voir plus
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Perol Maurice
Perol Maurice
Centre Léon-Bérard, Lyon, France
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France

Industries

Voir plus
AstraZeneca
91 collaboration(s)
Dernière en 2023
Edimark
66 collaboration(s)
Dernière en 2023
Janssen
58 collaboration(s)
Dernière en 2023
MSD
48 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Essai Clinique (National Cancer Institute)   21 mars 2024
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma: An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Essai Clinique (Roche)   20 mars 2024
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer: A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Essai Clinique (Dwight Owen)   12 mars 2024
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Essai Clinique (Jiangsu Alphamab Biopharmaceuticals Co., Ltd)   10 mars 2024
Promising Candidate Prognostic Biomarkers in FFDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine   07 mars 2024
NIPINEC: A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
ESMO 2023 : cancers bronchiques et thoraciques
Edimark   29 février 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
PAPILLON: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Essai Clinique (Janssen)   27 février 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024